Join the Lower Limb Spasticity group to help and get support from people like you.
Lower Limb Spasticity News (Page 2)
Cancer Incidence Increased for People With Multiple Sclerosis
WEDNESDAY, Oct. 9, 2024 – Cancer incidence is increased overall in people with multiple sclerosis (PwMS), with considerable differences depending on cancer type, age, and sex, according to a study...
Aggressive, Early Disease-Modifying Therapy May Slow MS Progression
FRIDAY, Sept. 27, 2024 – Reducing or preventing paramagnetic rim lesions (PRLs) could significantly slow multiple sclerosis (MS) progression, according to a study presented at the annual meeting of...
Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
THURSDAY, Sept. 26, 2024 – For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and...
Initial Symptoms of MS Could Guide Prognosis, Treatment
WEDNESDAY, Sept. 25, 2024 – Two key symptoms that can arise soon after a diagnosis of multiple sclerosis (MS) could predict how swiftly the illness will progress and suggest best treatment options,...
Higher Burden of Comorbidity Linked to Worse Clinical Outcomes in MS
MONDAY, Sept. 23, 2024 – For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according to a study published online Sept. 18 in JAMA...
Some People With MS May Need Earlier, Higher-Dose Meds
WEDNESDAY, Sept. 18, 2024 – Early, aggressive treatment of brain lesions caused by multiple sclerosis could help ward off faster decline in patients, a new study finds. Such treatment could prevent ...
Ipsen Announces Updated Indication for Dysport (abobotulinumtoxinA) for the Treatment of Spasticity in Children
CAMBRIDGE, Mass.--(BUSINESS WIRE) July 09, 2020 --Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration...
FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
DUBLIN, Oct. 24, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application...
Ipsen Announces FDA approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
June 16, 2017 – Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen) today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport (abobotulinumtoxinA) for injection...
Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
BASKING RIDGE, N.J., Aug. 1, 2016 /PRNewswire/ – Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug...
FDA Approves Botox (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity
DUBLIN, Jan. 22, 2016 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved Botox...